Abstract
The U.S. Food and Drug Administration (FDA) announced April 19 approval to market the first medical device to treat attention deficit hyperactivity disorder (ADHD). The prescription‐only device, called the Monarch external Trigeminal Nerve Stimulation (eTNS) System, is indicated for patients ages 7 to 12 years old who are not currently taking prescription ADHD medication.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
